STANOZOLOL: 176 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
176
Total FAERS Reports
38 (21.6%)
Deaths Reported
109
Hospitalizations
176
As Primary/Secondary Suspect
36
Life-Threatening
1
Disabilities
May 14, 1984
FDA Approved
Discontinued
Status
FDA Application: 012885 ·
First Report: 19960314 · Latest Report: 20250702
What Are the Most Common STANOZOLOL Side Effects?
#1 Most Reported
Drug abuse
93 reports (52.8%)
#2 Most Reported
Intentional product misuse
30 reports (17.0%)
#3 Most Reported
Left ventricular hypertrophy
26 reports (14.8%)
All STANOZOLOL Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug abuse | 93 | 52.8% | 28 | 54 |
| Intentional product misuse | 30 | 17.1% | 10 | 25 |
| Left ventricular hypertrophy | 26 | 14.8% | 13 | 13 |
| Off label use | 17 | 9.7% | 2 | 11 |
| Acute kidney injury | 15 | 8.5% | 0 | 15 |
| Testicular atrophy | 15 | 8.5% | 10 | 4 |
| Acute myocardial infarction | 14 | 8.0% | 0 | 12 |
| Toxicity to various agents | 14 | 8.0% | 14 | 2 |
| Hyperthyroidism | 13 | 7.4% | 0 | 13 |
| Focal segmental glomerulosclerosis | 12 | 6.8% | 0 | 12 |
| Drug-induced liver injury | 11 | 6.3% | 0 | 9 |
| Hypertension | 11 | 6.3% | 4 | 11 |
| Product use in unapproved indication | 11 | 6.3% | 0 | 10 |
| Acute respiratory distress syndrome | 10 | 5.7% | 0 | 10 |
| Chronic kidney disease | 10 | 5.7% | 0 | 10 |
| End stage renal disease | 10 | 5.7% | 0 | 10 |
| Muscle mass | 10 | 5.7% | 9 | 1 |
| Myocardial fibrosis | 10 | 5.7% | 9 | 1 |
| Myocarditis | 10 | 5.7% | 0 | 4 |
| Pneumonia | 10 | 5.7% | 0 | 9 |
Who Reports STANOZOLOL Side Effects? Age & Gender Data
Gender: 11.1% female, 88.9% male. Average age: 31.0 years. Most reports from: IT. View detailed demographics →
Is STANOZOLOL Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 1 |
| 2022 | 9 | 0 | 2 |
| 2023 | 5 | 4 | 5 |
| 2024 | 2 | 0 | 1 |
| 2025 | 1 | 0 | 0 |
What Is STANOZOLOL Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 61 |
| Muscle building therapy | 25 |
| Supplementation therapy | 14 |
| Performance enhancing product use | 12 |
| Drug abuse | 11 |
| Intentional product misuse | 8 |
| Aplastic anaemia | 7 |
STANOZOLOL vs Alternatives: Which Is Safer?
STANOZOLOL vs STAVUDINE
STANOZOLOL vs STELARA
STANOZOLOL vs STIRIPENTOL
STANOZOLOL vs STIVARGA
STANOZOLOL vs STRATTERA
STANOZOLOL vs STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 14 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 18C CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 19A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 19F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE A
STANOZOLOL vs STREPTOMYCIN
STANOZOLOL vs STREPTOMYCIN\STREPTOMYCIN
STANOZOLOL vs STREPTOZOCIN
STANOZOLOL vs STRIBILD
Official FDA Label for STANOZOLOL
Official prescribing information from the FDA-approved drug label.